0001104659-20-130082.txt : 20201127 0001104659-20-130082.hdr.sgml : 20201127 20201127171024 ACCESSION NUMBER: 0001104659-20-130082 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201124 FILED AS OF DATE: 20201127 DATE AS OF CHANGE: 20201127 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Perry George CENTRAL INDEX KEY: 0001725758 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38045 FILM NUMBER: 201355841 MAIL ADDRESS: STREET 1: C/O NEUROTROPE, INC. STREET 2: 205 EAST 42ND STREET, 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Neurotrope, Inc. CENTRAL INDEX KEY: 0001513856 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463522381 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1185 AVENUE OF THE AMERICAS STREET 2: 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: (973) 242-0005 MAIL ADDRESS: STREET 1: 1185 AVENUE OF THE AMERICAS STREET 2: 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 FORMER COMPANY: FORMER CONFORMED NAME: BlueFlash Communications, Inc. DATE OF NAME CHANGE: 20110223 4 1 tm2037145d8_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2020-11-24 0 0001513856 Neurotrope, Inc. NTRP 0001725758 Perry George C/O NEUROTROPE, INC. 1185 AVENUE OF THE AMERICAS, 3RD FLOOR NEW YORK NY 10036 1 0 0 0 Stock Option (right to buy) 0.972 2020-11-24 4 A 0 15000 0 A 2030-11-24 Common Stock 15000 15000 D The shares will immediately vest and become exercisable subject to and upon consummation of (1) the merger of PM Merger Sub 1, LLC with and into Metuchen Pharmaceuticals, LLC ("Metuchen"), with Metuchen surviving as a wholly-owned subsidiary of Petros Pharmaceuticals, Inc. ("Petros") and (2) the merger of PN Merger Sub 2, Inc. with and into Neurotrope, Inc. ("Neurotrope"), with Neurotrope surviving as a wholly-owned subsidiary of Petros (together, the "Mergers"). In the event the reporting person departs from the board of directors following the consummation of the Mergers, the options shall expire on the date that is one year from the date of the consummation of the Mergers. /s/ Robert Weinstein, Attorney-in-Fact 2020-11-27